LifeStance Health Group filings document the company's outpatient mental healthcare business, Nasdaq-listed common stock and public-company governance. Its 8-K reports furnish quarterly and annual results, Regulation FD presentations, operating metrics, cash flow commentary and capital allocation disclosures.
The filing record also covers proxy matters, director elections, executive compensation, officer and board changes, equity incentive awards, share repurchase authorization, and common stock offering documents under shelf registration statements. These disclosures describe governance structure, securities registration, material agreements, stockholder selling activity, repurchases, and the risks and reporting obligations associated with LifeStance's virtual and in-person outpatient care model.
LifeStance Health Group, Inc. (LFST) reported that Chief People Officer Ann Varanakis had 8,156 shares of common stock withheld on August 24, 2026 to satisfy tax withholding obligations upon vesting of restricted stock units. The shares were valued at $12.16 per share and were not sold in the open market, leaving her with 413,881 shares held directly after the transaction.
LifeStance Health Group, Inc. (LFST) director Teresa DeLuca reported selling 7,500 shares of common stock on 2026-08-14 at a weighted average price of $12.68 per share, in multiple trades between $12.68 and $12.695. According to the disclosure, this was a required “sell to cover” transaction to satisfy tax withholding obligations arising from the vesting of restricted stock units and does not represent a discretionary trade. Following this sale, DeLuca directly holds 97,093 shares of LifeStance common stock.
LifeStance Health Group, Inc. director Teresa DeLuca reported a sale of common stock. On 2026-08-13, she sold 20,441 shares of common stock at a reported price of $12.23 per share in a sale characterized as an open market or private transaction. Following this transaction, she directly holds 104,593 shares of LifeStance Health Group common stock.
LifeStance Health Group, Inc. has a significant shareholder group led by TPG GP A, LLC, together with James G. Coulter and Jon Winkelried as reporting persons. Through TPG VIII Lynnwood Holdings Aggregation, L.P., they report beneficial ownership of 98,101,407 shares of common stock.
This represents 25.7% of LifeStance’s common stock, based on 382,055,609 shares outstanding as of July 29, 2026. The shares are held indirectly through a chain of TPG entities, with voting and dispositive power shared among the reporting persons, who each disclaim beneficial ownership beyond their pecuniary interest.
Yawaog Enterprises Corp reported a planned sale of common stock under Rule 144. The reporting holder intends to sell 7,500 common shares through Fidelity Brokerage Services LLC on NASDAQ, with an indicated aggregate market value of $95,118.49 as of the proposed transaction.
The shares to be sold arise from restricted stock vesting on June 1, 2025, classified as compensation from the issuer. The filing also notes a prior sale of 20,441 common shares on August 13, 2026 for $249,993.43 during the preceding three months.
LifeStance Health Group, Inc. director Kenneth A. Burdick reported a sale of 500,000 shares of common stock on 2026-08-11 at a weighted average price of $11.51 per share, with individual trades between $11.50 and $11.665. Following this sale, he directly holds 2,970,810 shares and indirectly holds 46,511 shares through Burdick Family LLC.
LifeStance Health Group, Inc. Chief Technology Officer Vukasin Paunovich reported selling 44,394 shares of common stock on August 10, 2026, at $10.85 per share in an open market or private transaction. After this transaction, he directly holds 247,446 shares. The transaction is flagged as made pursuant to a Rule 10b5-1 trading plan, indicating it was executed under a pre-arranged plan.
LifeStance Health Group, Inc. reported that entities associated with TPG sold 13,643,207 shares of Common Stock at $10.62 per share in an indirect transaction. After this sale, TPG VIII Lynnwood Holdings Aggregation, L.P. directly holds 98,101,407 LifeStance common shares. The reporting persons are treated as indirect holders through a multi‑entity ownership chain and each disclaims beneficial ownership beyond any pecuniary interest.
LifeStance Health Group, Inc. reported that Chief Operating Officer Lisa K. Miller sold 47,912 shares of common stock on August 10, 2026 at $10.85 per share in an open-market or private transaction. After this sale, she directly holds 281,289 shares of LifeStance common stock. The transaction was affirmed as being made pursuant to a Rule 10b5-1 trading plan.